Elicit: Secukinumab and IL-17A: Cytokine Modulation Evidence

Secukinumab IL-17A receptor interaction: what evidence supports downstream cytokine reduction?

Evidence supporting downstream cytokine reduction includes rapid temporal correlation between IL-17A neutralization and suppression of IL-17-dependent mediators, quantitative reductions in cytokines and inflammatory biomarkers, pathway-specific effects with preserved immune function, cellular changes including neutrophil clearance and tissue normalization, and dose-response relationships, though most studies infer receptor interaction from downstream effects rather than measuring direct binding.

Abstract

Secukinumab, a fully human monoclonal antibody, selectively binds and neutralizes IL-17A, with target engagement demonstrated through accumulation of total IL-17A and decreased free IL-17A levels following treatment. Evidence supporting downstream cytokine reduction includes rapid suppression of the IL-23/IL-17 axis beginning at Week 1, with concurrent reductions in IL-17-dependent mediators including beta-defensin2, CXCL1, and CXCL8. Quantitative reductions include IL-6 decreases up to 38.4%, CRP reductions of 35.3%, and IL-17A declines of 42-68% over 52 weeks, with effects sustained for at least one year. The temporal correlation between IL-17A suppression at Week 4 and clinical/histological responses at Week 12, combined with pathway-specific effects (limited TNF-α modulation despite robust IL-17-dependent mediator reduction), establishes a causal link rather than simple correlation. Cellular evidence includes rapid neutrophil clearance, normalization of keratinocyte function, and histological resolution of tissue pathology.

However, most studies infer receptor interaction from downstream effects rather than measuring direct receptor binding or occupancy. The mechanistic sequence—from IL-17A binding through immediate pathway suppression to cytokine reduction and clinical improvement—is supported by dose-response relationships and preserved immune function (maintained T-cell activation and microbial response capacity). The evidence strongly supports that secukinumab’s IL-17A neutralization directly causes downstream cytokine reduction through selective pathway inhibition, though direct receptor binding studies would strengthen mechanistic understanding.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Records from Elicit search

Data extraction

We extracted each data column below from each paper:

Results

Characteristics of Included Studies

The systematic review identified 10 studies evaluating secukinumab’s mechanism of action and downstream effects on cytokine reduction. Studies varied in design, sample size, duration, and full text availability.

Characteristics of studies:

Study Full text retrieved? Study design Primary focus Sample size Duration
J. Krueger et al., 2023 Yes Randomized controlled trial (RCT) Clinical efficacy and mechanism of action 40 patients 16 weeks
K. Akhmedov et al., 2025 No Prospective observational study Clinical efficacy and disease activity assessment 184 patients 52 weeks
J. Merola et al., 2022 Yes Post hoc analysis of pooled phase 3/4 trials Cardiovascular risk factors and inflammatory biomarkers 9,197 patients from 19 trials At least 1 year
J. Krueger et al., 2019 Yes Randomized controlled trial (RCT) Clinical efficacy and mechanism of action Study population measured at multiple timepoints 12 weeks
P. Mease et al., 2015 No Randomized controlled trial (RCT) Clinical efficacy 606 patients 52 weeks
G. Bruin et al., 2019 Yes Open-label disease-drug-drug interaction study Mechanistic study focusing on pharmacokinetics and pharmacodynamics 24 patients Multiple assessments over time
K. Reich et al., 2015 Yes Randomized controlled trial (RCT) Clinical efficacy 100 subjects 12 weeks induction, follow-up to Week 56
I. McInnes et al., 2013 Yes Randomized controlled trial (RCT) Clinical efficacy and safety 42 patients 24 weeks
M. Genovese et al., 2012 No Randomized controlled trial (RCT) Clinical efficacy and safety 237 patients 16 weeks
M. Sande et al., 2018 No Open-label trial Mechanism of action 20 patients 12 weeks

Evidence of IL-17A Receptor Interaction

Studies evaluated secukinumab’s mechanism through multiple approaches, though most inferred receptor interaction from downstream effects rather than measuring direct binding. Secukinumab is described as a fully human monoclonal antibody that selectively inhibits IL-17A and binds to human IL-17A, neutralizing its bioactivity.

The mechanism involves direct neutralization of IL-17A’s biological activity, preventing IL-17A from binding to its receptor and triggering downstream inflammatory cascades. Target engagement was demonstrated through accumulation of total IL-17A after treatment initiation, with secukinumab binding to IL-17A reducing its clearance and decreasing free IL-17A levels. This binding creates antibody-antigen complexes that demonstrate target engagement at the molecular level.

Evidence of IL-17A pathway suppression varied across studies. One trial showed reduced expression of IL17A, IL17F, and IL17C mRNA with histological changes in target plaques. Another demonstrated suppression of the IL-23/IL-17 axis evident at Week 1 and continuing through Week 12, including reductions in upstream cytokine IL-23, drug target IL-17A, and downstream targets like beta-defensin2. Studies documented decreased synovial expression of IL-17A associated with clinical improvement, though several studies did not provide direct binding data or specific receptor interaction details.

The specificity of IL-17A inhibition was supported by evidence that secukinumab did not affect ex vivo T-cell activation, consistent with its targeted mechanism and favorable long-term safety profile.

Downstream Cytokine and Biomarker Reduction

Studies documented comprehensive reductions in inflammatory mediators following secukinumab treatment, though the specific cytokines measured and measurement approaches varied across investigations.

Cytokines/Biomarkers Measured:

  1. CRP, IL-6
    • Reduction in serum levels
    • Serum
    • RNASeq, qRT-PCR
    • Not specified
  2. IL-17A
    • Males: -42% (week 13), -55% (week 26), -68% (week 52); Females: -37% (week 13), -49% (week 26), -60% (week 52)
    • Not specified
    • ELISA
    • p<0.001
  3. Beta-defensin2, DEFB4A, S100 family, IL-17C, IL-36 family, CXCL8/IL-8, IL-19
    • Not explicitly quantified
    • Skin biopsy specimens
    • Transcriptomic profiling, GSVA
    • q < 0.05 for IL-17-dependent pathway scores
  4. IL-6, TNF-α, IL-1β, BD-2
    • IL-6: up to -38.4%; TNF-α: up to -16.8%; CRP: up to -35.3%
    • Serum
    • Multiplexed immunoassay, ELISA
    • Not mentioned
  5. CXCL1, CXCL8, IL-17A, IL-17F, TNF-α
    • Significant reductions in CXCL1 and CXCL8 mRNA by Week 2; limited effects on TNF-α mRNA
    • Skin biopsies
    • qPCR
    • Significant reductions implied
  6. hBD-2
    • Not specified
    • Serum
    • Not specified
    • p=0.0009
  7. CRP
    • Not specified
    • Serum
    • Not specified
    • Significant with 75mg, 150mg, 300mg vs placebo
  8. IL-17A, MMP-3
    • Not specified
    • Synovial (IL-17A), Systemic (CRP, ESR, MMP-3)
    • Histological analysis, qPCR
    • IL-17A: p=0.010; CRP, ESR, MMP-3: p<0.01

Temporal Correlation Between IL-17A Inhibition and Cytokine Reduction

The timeline of cytokine reduction following secukinumab administration showed remarkably early and sustained effects across multiple studies.

Study:

Study Earliest Detectable Changes Key Time Points Duration of Effect Effect Characterization
J. Krueger et al., 2023 Not specified Week 16 Not detailed beyond Week 16 Not specified
K. Akhmedov et al., 2025 Week 13 Weeks 13, 26, 52 Sustained over 52 weeks Sustained
J. Merola et al., 2022 Week 12 (psoriasis), Week 16 (PsA/axSpA) Week 12/16, Week 52 At least 1 year Sustained
J. Krueger et al., 2019 Week 1 Weeks 1, 4, 12 Continued through Week 12 Sustained
G. Bruin et al., 2019 Week 1 (hsCRP) Screening, baseline, weeks 1, 12, 24 hsCRP: week 1; BD-2: week 12; IL-6/TNF-α: week 24 Sustained until week 24
K. Reich et al., 2015 Week 2 Weeks 2, 12 Sustained until at least Week 12 Sustained
M. Sande et al., 2018 Not specified Week 12 Not specified Rapid improvements noted

The earliest documented cytokine changes occurred at Week 1, with suppression of the IL-23/IL-17 axis evident and continuing through Week 12. By Week 1, rapid reduction in hsCRP was observed, demonstrating immediate downstream effects. At Week 2, significant reductions appeared in IL-17A and IL-17F mRNA levels, along with marked decreases in keratinocyte-derived neutrophil chemoattractants like CXCL1 and CXCL8. Clinical responses to secukinumab were observed 2 weeks after a single infusion, associated with extensive clearance of cutaneous neutrophils parallel to normalization of keratinocyte abnormalities.

Supporting Biological Evidence

Beyond cytokine measurements, multiple studies documented cellular, histological, and functional changes supporting the IL-17A receptor-mediated mechanism.

Cellular Changes

Neutrophil dynamics showed consistent patterns. Significant clinical responses were associated with extensive clearance of cutaneous neutrophils parallel to normalization of keratinocyte abnormalities and reduction of IL-17-inducible neutrophil chemoattractants (e.g., CXCL1, CXCL8). Baseline biopsies revealed epidermal accumulation of neutrophils and formation of microabscesses in over 60% of cases, with neutrophils representing the numerically largest fraction of infiltrating cells containing IL-17. Following treatment, neutrophil clearance was evident at Week 2, with decreased synovial sublining macrophages (p=0.028) and neutrophils (p=0.004) associated with clinical improvement in joint counts.

Broader immune cell effects included reductions in lesional CD11c-positive dendritic cells and T cells, though these changes were more delayed compared to neutrophil clearance. Importantly, secukinumab did not affect ex vivo T-cell activation, and the capacity of peripheral blood cells to produce cytokines and chemokines upon stimulation with microbial antigens was not affected, suggesting preserved immune function despite cytokine reduction.

Histological Improvements

Tissue-level changes demonstrated resolution of pathological features. Secukinumab reversed plaque histopathology in the majority of patients and modulated a greater proportion of psoriasis disease transcriptome genes (72.1% vs 48.0%) compared to guselkumab, resulting in more histological responders (72.2% vs 53.3%). Specific improvements included reduced epidermal acanthosis, elongated rete ridges, and cellular infiltrates. Additional histological changes encompassed reduction in epidermal thickness, parakeratosis, acanthosis, and numbers of Ki67-positive proliferating epidermal cells.

Gene Expression Changes

Transcriptomic analyses revealed extensive modulation of the IL-17A pathway. Increased expression of IL17A, IL17F, and IL17C appeared in lesional skin, with secukinumab demonstrating suppression of IL-23, IL-17A, and downstream targets like beta-defensin2. Gene set variation analysis showed q values less than 0.05 for changes in IL-17-dependent pathway scores. Significant reduction in IL-17A and IL-17F mRNA levels occurred by Week 2. In synovial tissue, decreased expression of IL-17A was documented, and downregulation of hBD-2 mRNA in keratinocytes suggested normalization of keratinocyte function.

Biomarker Integration

Beyond cytokine measurements, inflammatory biomarkers showed consistent improvement. Significant reductions in CRP and ESR levels were observed, along with decreased MMP-3 production (p<0.01). The reduction in serum CRP and IL-6 levels indicated decreased systemic inflammation. Notably, high-sensitivity CRP decreased by up to 35.3%, and marked reductions in hBD-2 serum concentrations occurred.

One large pooled analysis specifically addressed the neutrophil-lymphocyte ratio (NLR), a predictive biomarker for cardiovascular disease. The decrease in NLR corresponded with decreased neutrophil counts, suggesting effects on neutrophil recruitment and clearance. Stabilization of NLR within physiological ranges suggested normalization of immune response, indicating that while inflammatory neutrophil activity was reduced, overall immune function was preserved.

Evidence Linking IL-17A Inhibition to Cytokine Reduction

Multiple lines of evidence established causal relationships between secukinumab’s IL-17A inhibition and downstream cytokine reduction rather than simple correlation.

Temporal Correlation

Studies consistently demonstrated tight temporal association between IL-17A inhibition and cytokine changes. Suppression of the IL-23/IL-17 axis occurred at Week 1 and continued through Week 12, with clinical and histological responses at Week 12 associated with suppression at Week 4. Secukinumab reduced hsCRP and NLR within weeks 12 to 16, sustained over 52 weeks. The reduction in serum CRP and IL-6 levels indicated a temporal relationship between IL-17A inhibition and cytokine reduction. Decrease in inflammatory cytokines like IL-6, TNF-α, and hsCRP followed secukinumab treatment, and significant IL-17A level reductions occurred at weeks 13, 26, and 52.

Dose-Response Relationships

Several studies provided dose-response evidence. Clinical and histological responses were associated with IL-17A inhibition in a dose-dependent manner, with normalization of epidermal markers more pronounced in the high-dose cohort. Consistent reduction in IL-17A levels occurred with a fixed dose of secukinumab (300 mg every two weeks). Clinically relevant decreases in DAS28-CRP and significant reductions in serum high sensitivity CRP levels appeared with higher doses (75 mg, 150 mg, and 300 mg) compared to placebo.

Mechanistic Explanations

Authors provided biological mechanisms linking IL-17A to cytokine cascades. IL-17A was identified as a critical node in maintaining psoriasis plaques, with its inhibition leading to reduction of downstream cytokines. IL-17A drives neutrophilic inflammation linked to cardiovascular disease, promotes atherosclerosis and neutrophil recruitment. The blockade of IL-17A’s effect on keratinocytes reduces neutrophil chemoattractants. Direct neutralization of IL-17A inhibits its biological activity, and IL-17A regulates cytokine expression, with secukinumab blocking this regulation.

Control Group Comparisons

Placebo-controlled designs demonstrated pathway specificity. Secukinumab versus guselkumab comparisons showed specificity to the IL-17A pathway, with no consistent effects observed in placebo groups. Significant improvements appeared in secukinumab groups compared to placebo, and effects were specific to secukinumab treatment groups versus placebo. A significant advantage for secukinumab over placebo in reducing hBD-2 levels was documented.

Cellular and Molecular Evidence

Direct mechanistic evidence emerged from multiple approaches. Significant changes in IL-17-dependent pathway scores were observed, with rapid clearance of neutrophils and reduction in IL-17A and IL-17F mRNA levels. Early reductions in IL-17A target genes correlated with clinical responses. Target engagement was demonstrated by increased total IL-17A levels, indicating IL-17A blockade. Clinical improvement linked to histological changes and decreased IL-17A expression, with hBD-2 identified as a downstream marker of the IL-17 pathway, its reduction attributed to IL-17A blockade.

The reduction in NLR and hsCRP associated with neutrophilic inflammation and atherosclerosis provided cellular evidence. Secukinumab did not affect ex vivo T-cell activation, demonstrating specificity.

Synthesis

The evidence across 10 studies, representing diverse populations and methodological approaches, converges on several key findings regarding secukinumab’s mechanism of downstream cytokine reduction through IL-17A inhibition.

Rapid and Sustained Pathway Modulation

The temporal data reveals a consistent pattern: IL-17A pathway suppression begins within the first week of treatment and is sustained for at least one year. This early onset (Week 1) with concurrent downstream effects argues against indirect mechanisms and supports direct IL-17A neutralization as the primary driver. The staggered kinetics of different biomarkers (hsCRP peaking at week 1, BD-2 at week 12, IL-6/TNF-α at week 24) likely reflects the hierarchical inflammatory cascade, where proximal mediators respond before distal effectors rather than indicating distinct mechanisms.

Pathway Specificity and Selectivity

The selective nature of secukinumab’s effects strengthens the mechanistic link. Limited effects on TNF-α mRNA contrast with robust reductions in IL-17-dependent mediators (CXCL1, CXCL8, beta-defensin2), demonstrating pathway specificity rather than general immunosuppression. The preservation of T-cell activation and maintained capacity to produce cytokines upon microbial stimulation further indicates targeted pathway intervention. This selectivity explains the favorable safety profile while achieving therapeutic efficacy.

Molecular Cascade from Target Engagement to Clinical Effect

The evidence supports a clear mechanistic sequence: secukinumab binds IL-17A, demonstrated by accumulation of total IL-17A and reduction in free IL-17A, which prevents receptor activation. This leads to immediate suppression of the IL-23/IL-17 axis, followed by rapid neutrophil clearance through reduced chemoattractants (CXCL1, CXCL8), normalization of keratinocyte function, and resolution of tissue pathology. The tight temporal correlation between IL-17A suppression at Week 4 and clinical/histological responses at Week 12 demonstrates this causal chain.

Quantitative Effects Across Disease States

While the magnitude of cytokine reduction varied across studies, likely reflecting different disease states and baseline inflammatory burdens, consistent patterns emerged. IL-6 reductions reached 38.4%, CRP decreased by 35.3%, and IL-17A itself declined by 42-68% over 52 weeks. The larger effects in high-risk patients with elevated baseline CRP (>4 mg/L for psoriasis, >10 mg/L for PsA/axSpA) suggest dose-response relationships where greater inflammatory burden permits larger absolute reductions, consistent with target-mediated drug disposition.

Integration of Mechanistic and Clinical Evidence

The mechanistic studies complement clinical trials by elucidating how downstream cytokine reduction translates to therapeutic benefit. Gene expression analyses showing 72.1% modulation of psoriasis disease transcriptome genes and significant changes in IL-17-dependent pathway scores (q<0.05) provide molecular validation of clinical improvements. The correlation between suppression of IL-17A target genes and clinical responses establishes the therapeutic relevance of cytokine reduction. Histological improvements—including reduced epidermal thickness, decreased neutrophil infiltration, and normalized keratinocyte proliferation—serve as intermediate endpoints linking molecular changes to patient-reported outcomes.

Limitations in Direct Receptor Binding Data

A notable gap exists in direct receptor binding or occupancy studies. Most evidence infers receptor interaction from downstream effects rather than measuring it directly. While the accumulation of total IL-17A provides indirect evidence of target engagement, and the specificity of effects strongly suggests receptor blockade, direct demonstration of receptor occupancy or competitive inhibition constants would strengthen mechanistic understanding. This represents an area where future studies could provide additional granularity.

Preserved Immune Function Despite Cytokine Reduction

A critical finding is that substantial cytokine reduction does not compromise protective immunity. The absence of effects on ex vivo T-cell activation, maintained capacity for cytokine production upon microbial challenge, and stabilization of NLR within physiological ranges collectively demonstrate that secukinumab selectively inhibits pathological IL-17A signaling while preserving homeostatic immune responses. This distinguishes IL-17A inhibition from broader immunosuppressive approaches and explains the manageable safety profile observed across trials.

References